Abstract
Erythrodermic cutaneous T-cell lymphoma (eCTCL) is currently considered as stage III disease and indicative of an unfavorable outcome. Further risk stratification depends on convened criteria for stage IV, based on tumor burden assessment on peripheral blood, lymph nodes, and noncutaneous tissues. Although flow cytometry (FC) is routinely used to assess peripheral blood involvement in eCTCL, gating strategies are not standardized and …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
